Caring Cross Reports Early Clinical Success with Anti-HIV CAR-T Therapy
Caring Cross Reports Early Clinical Success with Anti-HIV CAR-T Therapy
Caring Cross announced early clinical data from a first-in-human Phase I/IIa trial of anti-HIV CAR-T cell therapy at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston. The data, presented by Dr. Steven Deeks of the University of California, San Francisco, suggests that engineered T cells could provide durable viral suppression in HIV-positive patients who started antiretroviral therapy (ART) early in their infection course.
The clinical trial evaluated the safety and preliminary efficacy of Caring Cross's duoCAR-T therapy in ART-suppressed individuals. The approach uses patients' own T cells, which are genetically engineered using the company's proprietary duoCAR technology before reinfusion—a single-dose treatment designed to target HIV-infected cells directly.
Clinical Outcomes and Viral Suppression
According to the trial data, two consecutive patients in the conditioning arm achieved particularly notable outcomes. A single dose of CAR-T cell therapy strongly suppressed HIV in two people—one for nearly a year and the other for nearly two years—without requiring their usual medicines.
Dr. Mehrdad Abedi, Professor of Medicine and Director of Alpha Stem Cell Clinic at UC Davis and Clinical Co-Investigator for the trial, characterized the depth of viral suppression observed in these patients as "especially compelling." The clinical trial data suggested that anti-HIV CAR-T cell therapy could lead to durable viral control, particularly in patients who initiated HIV treatment early.
The trial is registered under NCT06252402, studying CMV-specific HIV-CAR T cells—a designation that indicates the engineered cells target both cytomegalovirus and HIV antigens simultaneously.
Broader CAR-T HIV Research Context
The Caring Cross results align with emerging data from parallel research programs exploring CAR-T applications for HIV treatment. Recent work published in Nature describes M10 CAR-T cells designed with three-fold biological functions: broad cytotoxic effects on HIV-infected cells, neutralization of cell-free viruses produced after latency reversal, and B-cell follicle homing capabilities.
In a phase I multicenter study of M10 CAR-T cells, 18 patients received two allogenic M10 cell infusions separated by 30 days. The results showed that 74.3% of M10 CAR-T cell infusions resulted in significant suppression of viral rebound, with viral loads declining by an average of 67.1%. Additionally, 10 patients demonstrated persistently reduced cell-associated HIV-1 RNA levels with an average decrease of 1.15 log10 over a 150-day observation period.
Separately, researchers have initiated a phase 1/2 trial of a dual CAR T cell therapy targeting gp120 for HIV treatment, expanding the range of viral targets under investigation.
Technical Approaches and Engineering Challenges
The duoCAR technology represents an evolution in CAR-T design specifically for persistent viral infections. Unlike traditional CAR-T applications in oncology, where the target is malignant cells, HIV-targeting CAR-T cells must identify and eliminate infected cells while the virus remains integrated into the host genome.
Parallel research efforts have explored complementary approaches to the shock-and-kill strategy. Researchers developed a targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery. This method achieved a 57.7% reduction of productively HIV-1 infected cells when applied to latently HIV-1 infected J-Lat 10.6 cells.
The conditioning regimen appears critical to the Caring Cross approach's success. While the specific conditioning protocol has not been detailed in public disclosures, the enhanced viral suppression in the conditioning arm suggests that preparative treatment may be necessary to optimize CAR-T cell engraftment and persistence.
Historical Pattern Recognition
We have seen this pattern before, when CAR-T therapies first emerged in oncology—initial single-patient successes followed by careful dose escalation studies that eventually revolutionized treatment for certain blood cancers. The HIV field has long sought a functional cure that would allow patients to maintain viral suppression without daily medication, much as CAR-T therapies now provide durable remissions in previously intractable malignancies.
The parallel between CAR-T cancer applications and HIV research extends beyond technical approach to regulatory pathway. Both require demonstrating safety in early-phase trials before efficacy endpoints become meaningful, and both face the challenge of engineering persistence in an immune system that may reject the modified cells over time.
Clinical Development Trajectory
The early-stage nature of these trials means that safety data will drive near-term development decisions. CAR-T therapies carry known risks including cytokine release syndrome and neurological toxicities, though these may manifest differently in HIV applications compared to oncology settings.
The patient population appears carefully selected—ART-suppressed individuals who initiated treatment early represent an optimal cohort for demonstrating proof-of-concept. Early treatment initiation typically correlates with smaller viral reservoirs, potentially making them more amenable to CAR-T-mediated clearance.
Looking ahead, the field will need to address several technical hurdles: optimizing CAR-T cell persistence, managing potential immune responses to the engineered cells, and determining whether single-dose treatments can achieve durable suppression across diverse patient populations.
The convergence of multiple research groups on CAR-T approaches for HIV suggests the technology platform has reached sufficient maturity to tackle persistent viral infections. While these early results require validation in larger cohorts, they represent progress toward the long-sought goal of medication-free viral control for HIV-positive patients.
